Loading…
Loading…
Seeks to achieve investment results that correspond to the MSCI USA IMI Health Care Index.
Is FHLC's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on October 21, 2013.
Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.
iShares Global Healthcare ETF provides exposure to international markets, while Fidelity MSCI Health Care Index ETF focuses exclusively on U.S.-based companies. Fidelity MSCI Health Care Index ETF maintains a significantly lower expense ratio than iShares Global Healthcare ETF.
Fidelity MSCI Health Care Index ETF (FHLC) offers a lower expense ratio and higher dividend than the iShares U.S. Healthcare ETF (IYH). IYH maintains a more concentrated portfolio, with 101 holdings compared to FHLC's 338 positions.